XTLB — X T L Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $9.78m
- $8.78m
- $0.45m
Annual cashflow statement for X T L Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.782 | 0.435 | -1.35 | -1.78 | -1.03 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.114 | -1.43 | 0.465 | 1.01 | -0.849 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.045 | -0.054 | -0.019 | 0.064 | 0.189 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -0.85 | -1.05 | -0.901 | -0.707 | -1.62 |
| Capital Expenditures | -0.001 | 0 | 0 | — | -0.054 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.033 | 0.008 | 0.036 | 0.041 | -0.79 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.032 | 0.008 | 0.036 | 0.041 | -0.844 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | — | 0.385 | 0 | 0 | 1.45 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.824 | -0.662 | -0.875 | -0.693 | -1.03 |